Causalis.ai is a healthtech company seeking to address a global challenge in oncology: finding the optimal balance between efficacy and tolerance in the treatment of cancer patients prior to starting the treatment.
Causalis’ focus is on lung cancer, the world's deadliest cancer.
Lung cancer patients are often diagnosed at a late stage of the disease and it is absolutely critical to get their treatment right on the first try.
Causalis.ai is developing causal AI technology that “understands” the complex cause and effect relationships in healthcare based on a patient's individual medical data. The company is developing a platform that will allow oncologists to make decisions hand-in-hand with their patients, taking into consideration the patient's prioritization between life expectancy and adverse events (quality of life).
Sentient is a Technion (Israel Institute of Technology) spin-off, AI-based, digital pathology company, leveraging cutting-edge machine learning to create synthetic pathology datasets for the purpose of overcoming existing data limitations in the field of computational pathology.
These synthetic datasets are validated, affordable, thoroughly labeled, and free from privacy concerns. They will enable faster and more accurate training and validation for highly accurate AI algorithms by medical research centers, digital health, pharma, and diagnostics companies, for all cancer tissue types, including the rarer forms.
Founded by Tomer Shlomi, Computer Sciences and Biology Professor at the Technion – Israel Institute of Technology, MetaSight employs its proprietary high-throughput mass-spectrometry technology and advanced computational analyses capabilities to enable untargeted multi-omics molecular biomarker discovery through unique access to a comprehensive HMO EHR database of more than 700 thousand people. Offering healthcare providers a cost-effective, rapid solution based on unprecedented robust data, MetaSight facilitates early disease diagnosis and the development of companion diagnostics for the benefit of patients worldwide.
Recognizing current respiratory system infection diagnostic methods are inadequate, invasive, and time-consuming, our stealth mode second cohort startup is currently developing an advanced medical device that utilizes proprietary technology and machine learning algorithms to accurately detect infections and their source. By means of a simple, non-invasive test, chronic lung patients are now offered a rapid, reliable diagnostic solution that enables early treatment: thereby preventing deterioration and subsequent hospitalizations.
Driven by a deep desire to address the challenges and inefficiencies associated with blood tests, LiteBC was founded by Technion researchers Or Peleg and Barry Loevsky to develop a groundbreaking diagnostic technology with the potential to revolutionize blood analysis in healthcare, and consequently, the way we monitor our body. LiteBc is developing its unique platform, Hemoscope, to offer a non-invasive, immediate, and portable alternative to traditional blood tests, eliminating the discomfort and pain associated with frequent testing, and enabling testing to be conducted from anywhere. The HemoScope serves to facilitate both the development of personalized medicine and its widespread adoption.
